Community Practice Knowledge Gaps and Geographic Variation

Dr. Schulte identifies significant knowledge gaps among community oncologists managing GIST, acknowledging that even experienced community practitioners may encounter only 2 to 3 patients annually. This limited exposure creates challenges in maintaining expertise with nuanced treatment decisions and sequencing strategies.

Key educational needs include consistent implementation of next-generation sequencing at diagnosis, which has become more accessible and provides crucial prognostic information for treatment selection. Molecular profiling can identify PDGFRA D842V mutations requiring avapritinib rather than standard KIT-targeted therapy, or rare entities like SDH-deficient tumors with dramatically different treatment paradigms.

Geographic and resource-related variability affects outcomes, with real-world data showing significant attrition across therapy lines. Community uncertainty about post-fourth-line management frequently triggers referrals to academic centers, highlighting need for clearer guidance on experimental options and clinical trial access.

The panel emphasizes early referral benefits for patients with rare molecular subtypes, such as those with germline SDH deficiency who may benefit from curative-intent approaches even with advanced disease, or NF1-associated tumors requiring different management strategies than sporadic GIST.

Dr. Heinrich notes that patients with NTRK fusions demonstrate exceptional responses to TRK inhibitors, emphasizing importance of comprehensive molecular profiling to identify actionable alterations that completely change treatment trajectory. Missing these rare but highly targetable mutations represents missed opportunities for superior outcomes.